Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

被引：0
|
作者：
Sharma, Padmanee
Krainer, Michael
Saad, Fred
Castellano, Daniel
Bedke, Jens
Kwiatkowski, Mariusz
Patnaik, Akash
Procopio, Giuseppe
Wiechno, Pawel
Kochuparambil, Samith Thomas
Thomas, Christian
Arija, Jose Angel Arranz
McCune, Steven L.
Hansen, Steinbjorn
Daugaard, Gedske
Amin, Neha P.
Wang, Yumeng
David, Justin M.
Pachynski, Russell Kent
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Montreal Hosp Ctr, Montreal, PQ, Canada
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Eberhard Karls Univ Tubingen, Tubingen, Germany
[6] Szpital Wojewodzki Mikolaja Kopernika w Koszalini, Oddzial Dzienny Chemioterapii, Koszalin, Poland
[7] Univ Chicago Med, Chicago, IL USA
[8] Ist Nazl Tumori Milano, Milan, Italy
[9] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[10] Minnesota Oncol, Minneapolis, MN USA
[11] Natl Ctr Tumor Dis, Heidelberg, Germany
[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[13] Northwest Georgia Oncol Ctr, Marietta, GA USA
[14] Odense Univ Hosp, Odense, Denmark
[15] Rigshosp, Univ Copenhagen Hosp, Copenhagen, Denmark
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
    Small, E. J.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Sun, J.
    Lin, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [23] Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?
    Thomas, Christian
    UROLOGIE, 2023, : 1281 - 1288
  • [24] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [25] STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).
    Boudadi, Karim
    Suzman, Daniel L.
    Luber, Brandon
    Wang, Hao
    Silberstein, John L.
    Taylor, Maritza N.
    Sullivan, Rana
    Dowling, Donna
    Harb, Rana
    Dittamore, Ryan Vance
    Meeker, Alan
    Luo, Jun
    Drake, Charles G.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    CANCER RESEARCH, 2012, 72
  • [27] Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial
    Shenderov, Eugene
    Boudadi, Karim
    Fu, Wei
    Wang, Hao
    Sullivan, Rana
    Jordan, Alice
    Dowling, Donna
    Harb, Rana
    Schonhoft, Joseph
    Jendrisak, Adam
    Carducci, Michael A.
    Eisenberger, Mario A.
    Eshleman, James R.
    Luo, Jun
    Drake, Charles G.
    Pardoll, Drew M.
    Antonarakis, Emmanuel S.
    PROSTATE, 2021, 81 (06): : 326 - 338
  • [28] Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC)
    Siegel, Adam Phillip
    Bryce, Alan Haruo
    Lin, Amy M.
    Friedlander, Terence W.
    Hsieh, Andrew Caleb
    Hang, Evelyn
    Weinberg, Vivian K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial
    Sonpavde, Guru
    Pond, Gregory Russell
    Clarke, Stephen John
    Vardy, Janette L.
    Wang, S. L.
    Paolini, Jolanda
    Lechuga, Mariajose
    Michaelson, M. Dror
    Smith, Matthew Raymond
    Chen, Isan
    Maneval, Edna Chow
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Caroline Jochems
    Jo A. Tucker
    Kwong-Yok Tsang
    Ravi A. Madan
    William L. Dahut
    David J. Liewehr
    Seth M. Steinberg
    James L. Gulley
    Jeffrey Schlom
    Cancer Immunology, Immunotherapy, 2014, 63 : 407 - 418
12345